drugset / Trial / NCT00214838
An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objectives of this study are to identify the maximum tolerated dose and to evaluate safety of atiprimod in patients with advanced cancer.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atiprimod | Small molecule | — | — |
Indications
No indication recorded.